lenvatinib + pembrolizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Melanoma
Conditions
Advanced Melanoma
Trial Timeline
Jan 30, 2019 → Oct 11, 2023
NCT ID
NCT03776136About lenvatinib + pembrolizumab
lenvatinib + pembrolizumab is a phase 2 stage product being developed by Eisai for Advanced Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03776136. Target conditions include Advanced Melanoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04645602 | Phase 1 | Recruiting |
| NCT04209660 | Phase 2 | Active |
| NCT03776136 | Phase 2 | Completed |
| NCT03609359 | Phase 2 | Completed |
| NCT03006887 | Phase 1 | Completed |
| NCT02501096 | Phase 1/2 | Completed |
Competing Products
20 competing products in Advanced Melanoma